REVIEW

The saga of XMRV: a virus that infects human cells but is not a human virus

This article has been corrected since Online Publication and an erratum has also been published

Maribel Arias and Hung Fan

Xenotropic murine leukemia virus-related virus (XMRV) was discovered in 2006 in a search for a viral etiology of human prostate cancer (PC). Substantial interest in XMRV as a potentially new pathogenic human retrovirus was driven by reports that XMRV could be detected in a significant percentage of PC samples, and also in tissues from patients with chronic fatigue syndrome (CFS). After considerable controversy, etiologic links between XMRV and these two diseases were disproven. XMRV was determined to have arisen during passage of a human PC tumor in immunocompromised nude mice, by activation and recombination between two endogenous murine leukemia viruses from cells of the mouse. The resulting XMRV had a xentropic host range, which allowed it to replicate in the human tumor cells in the xenograft. This review describes the discovery of XMRV, and the molecular and virological events leading to its formation, XMRV infection in animal models and biological effects on infected cells. Lessons from XMRV for other searches of viral etiologies of cancer are discussed, as well as cautions for researchers working on human tumors or cell lines that have been passed through nude mice, including potential biohazards associated with XMRV or other similar xenotropic murine leukemia viruses (MLVs).

Emerging Microbes and Infections (2014) 3, e25; doi:10.1038/emi.2014.25; published online 9 April 2014

Keywords: chronic fatigue syndrome; endogenous retrovirus; murine leukemia virus; prostate cancer; retrovirus; XMRV

INTRODUCTION

Retroviruses have been associated with diseases in both animals and humans. The first retroviruses discovered caused cell-free transmission of sarcomas and acute leukemias in chickens.1,2 Although these findings were initially met with skepticism, subsequent studies led to discovery of mouse mammary tumor virus and murine leukemia virus (MLV).3,4 Studies of animal retroviruses also revealed the existence of endogenous (germline-transmitted) retroviruses,5–7 and of viral oncogenes and cellular proto-oncogenes.8

The existence of oncogenic animal retroviruses raised the question of whether human oncogenic retroviruses also exist. After several false starts, clinical and epidemiological studies in Japan ultimately led to isolation of the first oncogenic human retrovirus, Human T-cell leukemia virus type I (the causative agent of adult T-cell leukemia) in 1980.9,10 Subsequently, the retrovirus HIV-1 was identified as the cause of acquired immunodeficiency syndrome; together these two viruses (and the related viruses human T-cell leukemia virus type II and HIV-2) currently infect 40–50 million people worldwide. These are the only well-documented infectious human retroviruses discovered to date. However, there have been suggestions of other retroviruses in human disease, including breast cancer and primary biliary cirrhosis.11,12 Human endogenous retroviruses have also been implicated in cancers and autoimmune diseases.13,14

RETROVIRUSES

Retroviruses have been reviewed extensively,15 and a brief summary is provided here. They are enveloped RNA-containing viruses, with positive sense RNA genomes of 8–12 kb in length. All retroviruses carry three genes gag, pol and env that encode the viral core proteins, enzymes (reverse transcriptase, integrase and protease) and envelope proteins respectively. During infection virions bind to receptors on the cell surface and the viral cores are internalized and partially uncoated. In the infected cell, core-associated reverse transcriptase reverse-transcribes the viral RNA into double-stranded viral DNA that enters the nucleus where it is integrated (by way of integrase) into host DNA to generate the provirus. The provirus is then transcribed by cellular RNA polymerase II into full-length viral RNA. This RNA is transported to the cytoplasm (with and without splicing) to give viral mRNAs for synthesis of viral proteins; unspliced viral RNA is also transported to the cytoplasm as genomes for new virus particles. New virions bud from the cell surface without lysing the infected cell.

As a consequence of reverse transcription, the viral DNA is longer than the viral RNA by the presence of long terminal repeats (LTRs) at either end. In the integrated provirus, the LTRs contain the promoter and enhancer sequences necessary for initiation of viral transcription, as well as sequences for cleavage/polyadenylation. The LTR is subdivided into three regions: U3, R and U5; the promoter and enhancer sequences are contained in the U3 region.
The mechanism by which most retroviruses induce cancers is incidental activation of proto-oncogenes. Normally during infection retroviral DNA is inserted at multiple, almost random sites in the cellular DNA. However, independent tumors induced by the same retrovirus often show integration at common insertion sites. These integration sites are largely at or near cellular proto-oncogenes—normal cell genes involved in positive stimulation of cell division and growth. The viral DNA leads to overexpression of the proto-oncogene RNA and protein, either by read-through transcription from the viral LTR (promoter insertion) or activation of the proto-oncogene’s own promoter by the retroviral enhancers. A subset of retroviruses that rapidly induce cancers carry viral oncogenes—genes that directly cause oncogenic transformation. The viral oncogenes result from capture of cellular proto-oncogenes into the viral genome.

MURINE LEUKEMIA VIRUSES

MLVs are prototypical gammaretroviruses. They are further classified based on the species that they can infect: ecotropic viruses infect only cells of mouse or rat origin, xenotropic viruses infect only non-mouse cells; and amphotropic and polytropic viruses, which infect both mouse cells and cells of other species (Table 1). MLVs such as Moloney and Friend MLV (M- and F-MLV) induce T-cell and erythroid/myeloid tumors respectively. They have been extensively studied at the molecular and cellular level, and used as model systems for leukemogenesis.

Table 1 MuLV subgroup classification by host range

| MuLV subgroup    | Host range          | Receptor |
|------------------|---------------------|----------|
| Ecotropic MuLV   | Mouse or rat cells  | CAT-1a   |
| Amphotropic MuLV | Mouse and non-mouse cells | PIR-2a |
| Xenotropic MuLV  | Non-mouse cells     | XPR-1b   |
| Polytropic/MCF   | Mouse and non-mouse cells | XPR-1b |

a Only CAT-1 from mice and rats binds ecotropic MuLV Env protein.
b Xpr-1 of mouse cells binds polytropic MuLV Env protein, but it does not bind xenotropic MuLV Env. Xpr-1 from non-murine species binds both xenotropic and polytropic Env.

Another situation in which endogenous MLVs of mice have been activated is passage of human tumor xenografts in immunodeficient (e.g., nude) mice, a common procedure employed in cancer biology for establishment or passage of human tumor cell lines. During xenograft passage, XMVs can become activated; they do not replicate in the mouse since mouse cells cannot be infected by their envelopes; however, human cells are susceptible. The infection of human xenografts by xenotropic MLVs after passage through nude mice has been known for many years.

DISCOVERY OF XMRV

Discovery in 2006 of a potential human retrovirus associated with prostate cancer (PC) originated from studies of familial PC. A familial form of PC had been genetically mapped to the gene encoding ribonuclease L (RNase L). RNase L is an effector molecule in the interferon antiviral response, and individuals with an inherited increased PC susceptibility were found to be homozygous for a polymorphic RNase L allele with lower enzymatic activity (R462Q). The fact that RNase L is involved in innate immunity suggested that such individuals could be more susceptible to a virus that induces PC. Based on this hypothesis investigators prepared cDNAs from familial and non-familial PC cases and hybridized them to a ‘virochip’ that contained DNA sequences for genes of all known viruses. A virus ‘hit’ was found for the familial PC tissues, and it was for xenotropic MLV; non-familial PCs appeared to have a lower frequency of hybridization with X-MLV. The hybridizing cDNAs were recovered from the virochip and cloned, and the corresponding virus was designated XMRV, and reported as a novel retrovirus potentially involved in human PC.

In a follow-up publication the same investigators described an infectious XMRV clone (VP62) reconstituted from XMRV cDNAs from a PC patient. The clone produced infectious virus that could replicate in human PC cells and also in hamster cells engineered to express the X-MLV receptor XPR-1, indicating that it was xenotropic in host range. Significantly, the authors sequenced the host cell DNA adjoining integrated XMRV proviruses in primary PC tissues from two XMRV positive cases, and the cellular sequences were human. This supported the conclusion that XMRV was a retrovirus that was infecting human cells, and not likely a polymerase chain reaction (PCR) artifact (however, as it was later determined that the XMRV-infected human cells represented contamination with an infected human PC cell line, as will be discussed below).

Despite the promising initial results, follow-up studies were inconsistent in associating XMRV infection with PC. For instance an early study of a European PC cohort indicated that overall levels of XMRV detection were low (~1%), and not associated with homozygosity for the RNase L R462Q allele. On the other hand, immunohistochemistry for XMRV Gag protein in a US cohort of human PC samples detected reactivity in a significant fraction of tumors, with a positive correlation for high-grade PC tumors. In this study, there was also no correlation between XMRV reactivity and RNase L status, which suggested that that XMRV infection might be more widely distributed in PC patients. Also, XMRV LTR activity was reported to be significantly higher in primary stromal fibroblasts isolated from prostate tissue or the PC cell line LNCaP compared to other cell types, suggesting that the virus might replicate and express more efficiently in prostate tissue. An important finding in 2009 was that the cell line 22Rv1, derived from a human PC patient, harbored multiple copies of XMRV DNA and expressed it highly. However, other subsequent studies failed to detect XMRV in prostate tissue, serum or peripheral blood mononuclear cells (PBMC) of patients with PC from the United States and Europe.
Interest in XMRV was further spurred in 2009 by Lombardi et al., who reported XMRV in 67% of PBMCs isolated from patients with chronic fatigue syndrome (CFS, also called myalgic encephalomyelitis or ME), a condition for which an etiology has not been found. Detection was by PCR for XMRV DNA, presence of anti-XMRV antibodies in patient sera and isolation of infectious virus from patient CD4+ T cells by coculture with susceptible cells. The following year, Lo et al. reported detection by PCR of polytropic MLV-related sequences, but not XMRV, in CFS patients; although this was not a finding of XMRV, it further suggested infection of gammaretroviruses in CFS patients. Despite these early reports and the excitement they generated in the CFS patient community, the association of XMRV with CFS has been disproven. Many studies have failed to detect XMRV in CFS cohorts around the globe. Surveys also have not identified XMRV infection in the general human population or in humans at high risk for viral infections (e.g., HIV-1-infected individuals).

When XMRV was first described, it was noteworthy that isolates from different patient sources were nearly identical. A hallmark of retroviruses is that they undergo significant mutation during replication, due to the error-prone nature of reverse transcriptase. When multiple rounds of infection take place in an infected individual (e.g., HIV-1 infection in humans), this can lead to extensive mutations in the viral genome. Moreover, an important set of host cell restriction factors, the apolipoprotein B editing complex (APOBEC) proteins, restrict retroviral replication by inducing G→A mutations during reverse transcription, and XMRV was found to be sensitive to human APOBEC3G. Thus, the lack of sequence variation in different XMRV isolates raised the question as to whether the virus was replicating in humans. On the other hand, human T-cell leukemia virus type-1 is an established oncogenic retrovirus of humans, and it also exhibits minimal sequence variation in and between patients. This might reflect maintenance of infection by persistently infected cells, along with infrequent rounds of new infection.

THE ORIGINS OF XMRV
In 2011, Paprotka et al. were able to deduce the origins of XMRV. They focused on the 22Rv1 cell line that harbors multiple XMRV proviruses and produces large amounts of virus. These cells resulted from multiple xenograft passages of a PC patient tumor (CWR22) in nude mice, and the investigators tested if XMRV could have arisen during the in vivo passaging. While the original patient tissue was not available, early and late xenograft passage samples were obtained, including a late passage that was an immediate precursor of 22Rv1 cells. PCR analysis using XMRV-specific primers showed that the early xenografts did not harbor XMRV, indicating that the original patient tumor was not infected. However, the late passage xenografts and the 22Rv1 cells were positive for XMRV, suggesting that XMRV arose during the in vivo passage in nude mice by infection from activated endogenous MLV proviruses. Analysis of the endogenous MLVs in nude mice identified two with stretches of high complementarity (virtual identity) to regions of XMRV: PreXMRV-1 and PreXMRV-2. It was possible to generate the XMRV genome by six crossovers between these two endogenous viruses, followed by three single-base substitutions and one nucleotide addition (Figure 1). Retroviral recombination requires copackaging of two heterologous viral RNAs into a virus particle, followed by template switching during reverse transcription in a subsequently infected cell. The PreXMRV-2 genome has open reading frames for all genes; presumably it was activated from a mouse cell during the xenografting where it also ultimately copackaged a PreXMRV-1 RNA. Thereafter, recombination and propagation of the recombinant (XMRV) took place in the human PC cells in the xenograft since human cells are susceptible to infection by xenotropic MLVs. More recent tissue culture experiments have confirmed that recombination between PreXRMV-1 and PreXMRV-2 can yield replication-competent xenotropic viruses, although the exact crossovers in the in vitro generated recombinants were different from those of XMRV.

The fact that XMRV arose from multiple recombinations between PreXRMV-1 and -2 had another implication. The high sequence identity between XMRVs detected in different studies, coupled with the multiple crossovers involved in formation of the virus, made it likely that all of the XMRVs identified in human patient samples did not arise independently, but that they likely came from the 22Rv-1 cell line. Detection of XMRV in human tissues generally required multiple rounds of PCR, which could have resulted in amplification of trace amounts of XMRV-infected cells or plasmids. Subsequently, many of the tumor samples initially reported to be XMRV positive were re-analyzed and found to be contaminated with the VP62 MLV plasmid or 22Rv1 cells, leading to an initial partial retraction of the paper by the authors. A large-scale collaborative blinded analysis tested PBMCs of CFS patients in independent laboratories and led to the conclusion that the initial reports of XMRV in the general population also resulted from laboratory contamination, or from incorrect initial identification of positive samples due in part to contaminating mouse DNA in PCR reagents. Subsequently, the key papers reporting discovery of XMRV and its association with PC or CFS were retracted.

XMVR INFECTION IN EXPERIMENTAL ANIMALS
Despite the fact that XMRV is not a human virus circulating in humans, it is an infectious virus. Experimental infection of XMRV in three animal species has been reported: rhesus macaques, pigtail macaques and Mus pahari mice. Mus pahari are infectable by xenotropic MLVs due to a polymorphism in the Xpr1 receptor. In all three animals, XMRV infection could be detected shortly after infection (the first few weeks) by RT-PCR for viral RNA in plasma
and/or PCR for viral DNA in tissue samples. After this phase, however, circulating virus became undetectable, although long-term persistence of proviral DNA in PBMCs or tissues could be detected by PCR in some cases. Persistence of low level viral infection was also suggested by prolonged immunological responses to XMRV in all cases. In *Mus pahari* mice, passage of infected cells from mother to offspring was also found. Similar to the tissue culture studies, the tissue tropism of XMRV *in vivo* seems to include a range of cell types: blood (lymphoid and other cell types) and epithelial cells. In rhesus macaques, XMRV infection in the prostate and the reproductive tract was significant early after infection, resembling the *in vitro* preference of XMRV replication for prostate cells. Infection in the prostate was also observed in *Mus pahari*. Consistent with the *in vitro* sensitivity of XMRV to human and murine APOBEC3s, G→A hypermutations were observed in XMRV proviruses from PBMCs in infected pigtail macaques and *Mus pahari*. Thus, in all three reported animal models, XMRV establishes limited infection, although traces of the virus persist for long times. No pathological consequences of XMRV infection were reported, although the number of subjects was small and the time durations were not extensive. We have studied infection of XMRV in Sprague–Dawley rats. Consistent with the other animal models, there was evidence for persistent infection (up to one year) as measured by DNA PCR, and infected cells were present in multiple tissues, both hematopoietic and epithelial (including prostate). However, G→A hypermutation was not observed.

**BIOLICAL EFFECTS OF XMRV INFECTION**

Even though XMRV is not associated causally with human PC, the virus has biological effects on infected cells in culture, some of which may have contributed to selection for the virus in 22Rv1 cells. When rat 208F cells were infected *in vitro* by XMRV obtained from infected hamster HT1080 cells, a small number of transformed foci formed, and one of the foci contained an acute transforming version of XMRV that had transduced the N-ras cellular oncogene from HT1080. 

We have found that XMRV infection of rat NRK kidney epithelial cells leads to an increase in growth rate of the infected cells and a shift to a more mesenchymal growth pattern.

The possibility that XMRV may affect the growth properties of human prostate epithelial cells has also been examined. XMRV infection of LNCaP cells accelerates *in vitro* cell proliferation, transformation and invasion of cells into Matrigel; these activities were mediated by downregulation of the cyclin/cyclin-dependent kinase inhibitor p27 (Kip1). A role for XMRV in cell proliferation or tumorigenesis was also reported by Steider et al. who found that shRNA-induced suppression of XMRV in 22Rv1 cells resulted in reduced migration and cytokine release *in vitro*. Furthermore, when implanted into nude mice, the shRNA-treated cells showed decreased angiogenesis, reduced tumor size and increased necrosis of the primary tumor. A positive effect of XMRV on 22Rv1 cell growth could explain why the virus was selected during establishment of these cells.

Very recently, a report by Murgai et al. again provided evidence for effects of XMRV or similar viruses in growth of prostate epithelial cells. LNCaP prostate epithelial cells were passaged through nude mice, and some of the resulting sublines showed enhanced metastatic potential. One such subline, B4, was found to be producing a novel xenotropic MLV (B4rv) that resulted from activation/recombination of three endogenous MLVs. Strikingly, the Env region of B4rv was largely derived from PreXMRV-1, which is also the endogenous virus that contributed most of the Env region to XMRV. *In vitro* infection of LNCaP cells with either B4rv or XMRV resulted in enhanced metastatic potential, which was associated with disruption of tumor vasculature maturation. Chimeric viruses indicated that the growth-promoting effects were determined by the xenotropicEnv protein. It is noteworthy that passage of human PC xenografts through nude mice has twice given rise to MLVs that arise from recombination of two or more endogenous MLVs, with the envelope partner being largely derived from PreXMRV-1. On the other hand, in other human xenografts of human leukemias and solid tumors (including PCs) through nude mice, endogenous xenotropic viruses were also recovered, but they appear to be direct activations of B10 xenotropic virus 1 or other replication-competent X-MLVs without recombination. Thus, the nature of xenotropic MLVs recovered from human xenograft passages in nude mice may be influenced by tissue-specific and virus-specific growth-promoting properties of the activated viruses, as well as the genetic background of the nude mice, some of which do not harbor PreXMRV-1 or -2.

**LESSONS FROM XMRV**

Identifying infectious agents associated with human cancer is an important topic; currently 20%–25% of human cancers have a viral etiology, and it is certainly possible that additional viruses or bacteria are involved. The experience with XMRV provides several lessons for researchers engaged in hunts for new infectious agents associated with human diseases (cancers and others). First, XMRV underlines the previously known risk of passing human tumor tissues through immunocompromised mice. While such passages have been effective in establishing tumor cell lines, the acquisition of activated endogenous MLVs or other retroviruses (not to mention other murine viruses) should be routinely monitored in the resulting lines. It should be emphasized that the nude mice used in the tumor xenograftpassaging did not themselves produce substantial replication-competent MLVs. Rather, low-frequency activation of endogenous viruses with replication potential for human cells can result in production and spread in the human xenografts. Surveys of previously derived human cell lines have revealed significant numbers that are infected with X-MLVs.

Second, if a xenotropic MLV is activated or amplified in a human tumor cell line, these cells can serve as a source for viral contamination of other cell lines. If investigators are passaging several cell lines in the same laboratory without employing precautions to prevent viral contamination, spread of virus from a productively infected cell line to other cell lines can occur unnoticed. In a survey by Zhang et al. there was evidence for spread of X-MLVs from xenograft-derived cell lines to other cell lines passaged in the same laboratory, including apparent spread of XMRV from 22Rv1 cells to a colorectal cancer cell line. Indeed, the original discovery of XMRV likely reflected detection of contamination in PC samples of DNA or RNA from 22Rv1 cells.

The use of high cycle PCR amplifications to detect XMRV in patient samples also likely resulted in detection of low levels of contaminating sequences in several studies. One obvious source was XMRV plasmids maintained in the same laboratory. More subtle sources of contamination result from the fact that many of the original ‘XMRV-specific’ PCR primers used could also amplify endogenous PreXMRV-1 or PreXMRV-2 sequences from mouse DNA. Thus contamination of human patient samples with mouse DNA could give false positives. One potential source was the carryover of mouse DNA to patient samples if the same microtome was used for sectioning of both mouse and human tissues. Moreover mouse DNA in common laboratory reagents such as PCR buffers and RT-PCR kits gave false positive results for XMRV. Some commercial *taq* polymerases are prepared with use of a mouse monoclonal antibody, and trace amounts
of DNA from the mouse hybridoma cells presumably resulted in positive PCR signals for XMRV.91,92

POTENTIAL BIOHAZARDS ASSOCIATED WITH XMRV

While the association of XMRV with human PC or CFS has been disproven, the fact remains that it is a replication-competent MLV with xenotropic host range, and human cell lines such as LNCaP can be infected in culture.26,31 Thus, there is potential biohazard risk from this virus for humans. Moreover, the fact that productively infected cells such as 22Rv-1 have spread infection to other cell lines, raises the possibility that laboratory workers could have been unknowingly exposed to the virus. However, several facts reduce the risk of human infection by XMRV. Gammaparetroviruses require cell division for productive infection, since entry of the viral DNA into the nucleus for integration is dependent on breakdown of the nuclear envelope during mitosis.13 In human adults, the most susceptible tissues would be those where there is rapid cell division, and for gammaparetroviruses, this is typically the hematopoietic system, e.g., lymphocytes and other mononuclear cells. Cells or tissues where there is little cell division would be relatively resistant to infection. Hematopoietic cells generally have high levels of APOBEC3G, which potently inhibits XMRV infection;63–65 thus, the main cellular targets in humans are likely to be relatively resistant to infection. Indeed XMRV is restricted for in vitro infection of human PBMCs,93 and in the animal infection experiments, hyper-mutation of XMRV resulting from APOBEC3 restriction was observed,67,77 which may have resulted in lack of continued productive infection. On the other hand, PC cell lines have been reported to express low or undetectable APOBEC3G,63–65 although this conclusion has been challenged.94 In addition, the XMRV LTR has androgen response elements in its LTR enhancers,31 which would favor transcription of the viral DNA in infected prostate cells. Thus theoretically cells of the prostate could support XMRV replication more efficiently. However, scenarios by which the relatively low number of dividing cells in the prostate could become exposed to XMRV by laboratory contamination seem rather implausible. At a practical level, a survey of laboratory workers highly exposed to mice detected no evidence for XMRV or MLV infections.95 Nevertheless, the possibility of infection by XMRV (or other xenotropic MLVs) in humans (particularly in the laboratory setting) should be considered. At a minimum, standard biosafety precautions for handling xenotropic viruses as well as screening of laboratory cell lines for infection with xenotropic MLVs is important.

ACKNOWLEDGMENTS

This work was supported in part by the Cancer Research Coordinating Committee of the University of California, and by National Science Foundation grant DGE-0638751. Support of the University of California, Irvine Cancer Research Institute and the UCI Chao Family Comprehensive Cancer Center (grant P30CA662203 from the National Cancer Institute) is acknowledged. We thank Takayuki Nitta and Tom Hsu (University of California, Irvine) for helpful discussions.

1 Roux P. A Sarcoma of the fowl transmissible by an agent separable from the tumor cells. J Exp Med 1911; 13: 397–411.
2 Ellerman V, Bang O. Experiment elle leukamie be hunden. Zentralbl Bakteriol 1908; 46: 595–609.
3 Bittner JJ. Some possible effects of nursing on the mammary gland tumor incidence in mice. Science 1936; 84: 162.
4 Gross L. Development and serial cell-free passage of a highly potent strain of mouse leukemia virus. Proc Soc Exp Biol Med 1957; 94: 767–771.
5 Lieberman M, Kaplan HS. Leukemogenic activity of filtrates from radiation-induced lymphoid tumors of mice. Science 1959; 130: 387–388.
6 Hohn O, Krause H, Schellino E, Hufeisen DJ. Type-C virus in human lymphoid cells. Science 1962; 136: 971–972.
7 Vogt PK, Friis RR. An avian leukemia virus related to RSV(O): properties and evidence for helper activity. Virology 1971; 43: 233–234.
8 Muhlbock O. Note on a new inbred mouse-strain GR-A. Eur J Cancer 1965; 1: 123–124.
9 DiMaio D, Fan H. Virus, cell transformation, and cancer. In: Knipe DM, Howley PM (ed.) Fields virology, 6th ed. Vol. 1. Philadelphia, PA: Lippincott Williams & Wilkins, 2013: 153–188.
10 Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of a C-type retrovirus particle from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 1980; 77: 7415–7419.
11 Yoshiida M, Miyoshi I, Hinuma Y. Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci USA 1982; 79: 2033–2035.
12 Xu L, Sakalian M, Shen Z, Loss G, Neuberger J, Mason A. Cloning the human betaretrovirus proviral genome from patients with primary biliary cirrhosis. Hepatology 2004; 39: 151–156.
13 Muhlbock CS, Linnebacher M. Human endogenous retroviruses and cancer: causality and therapeutic possibilities. World J Gastroenterol 2012; 18: 6027–6035.
14 Romanish MT, Cohen CJ, Mager DL. Potential mechanisms of endogenous retroviral-mediated genomic instability in human cancer. Semin Cancer Biol 2010; 20: 246–253.
15 Goff SP. Retroviridae. In: Knipe DM, Howley PM (ed.) Fields virology, 6th ed. Vol. 2. Philadelphia, PA: Lippincott Williams & Wilkins, 2013: 1424–1473.
16 Hayward WS, Neel BG, Astrin SM. Activation of a cellular onc gene by promoter insertion in ALV-induced lymphoid leukemia. Nature 1981; 290: 475–480.
17 Han T. Leukemogenesis by Moloney murine leukemia virus: a multistep process. Trends Microbiol 1997; 5: 74–82.
18 Jahnner D, Jaenisch R. Retrovirus-derivated neo methylation of flanking host sequences correlates with gene inactivity. Nature 1985; 315: 594–597.
19 Ch'ang LY, Yang WK, Myer FE, Yang DM. Negative regulatory element associated with gene silencing and retrovirus integration in ALV-induced lymphoid leukosis. Proc Natl Acad Sci USA 1977; 74: 789–792.
20 Achong BG, Trumper PA, Giovanna BC. C-type virus particles in human tissues transplanted into nude mice. Br J Cancer 1976; 34: 203–206.
21 Todaro GJ, Arnstein P, Parks RP, Levine H, Huesdel RJ. Type-C virus in human rhabdomyosarcoma cells after inoculation into NIH Swiss mice treated with antithymocyte serum. Proc Natl Acad Sci USA 1973; 70: 859–862.
22 Traika TS, Yee CL, Rabson AB et al. Murine type C retroviruses and intratumoral A particles in human tumors serially passaged in nude mice. J Natl Cancer Inst 1983; 71: 591–599.
23 Casey G, Neville PJ, Plummer SJ et al. RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat Genet 2002; 32: 581–583.
24 Urisman A, Molinaro RJ, Fischer N et al. Identification of a novel gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. PLoS Pathog 2006; 2: e25.
25 Dong B, Kim S, Hong S et al. An infectious retrovirus susceptible to an IFN antiviral pathway from human prostate tumors. Proc Natl Acad Sci USA 2007; 104: 1655–1660.
26 Alter HJ, Mikovits JA, Switzer WM et al. A multicenter blinded analysis indicates no association between chronic fatigue syndrome/myalgic encephalomyelitis/cfs and either xenotropic murine leukemia virus-related virus or polytropic murine leukemia virus. MBio 2012; 3: e00266-12.
27 Rusinevichtong A, das Gupta J, Elias PS, Silverman RH, Chow SA. Analysis of single-nucleotide polymorphisms in patient-derived retrovirus integration sites reveals contamination from cell lines acutely infected by xenotropic murine leukemia virus-related virus. J Virol 2011; 85: 12830–12834.
28 Fischer N, Heltwein O, Schutz C et al. Prevalence of human gammaretrovirus XMRV in sporadic prostate cancer. J Clin Virol 2008; 43: 277–283.
29 Schlager R, Choe DJ, Brown KR, Thaker HM, Singh IR. XMRV is present in malignant prostatic epithelium and is associated with prostate cancer, especially high-grade tumors. Proc Natl Acad Sci USA 2009; 106: 16351–16356.
30 Rodriguez JJ, Goff SP. Xenotropic murine leukemia virus-related virus establishes an efficient spreading infection and exhibits enhanced transcriptional activity in prostate carcinoma cells. J Virol 2010; 84: 2556–2562.
31 Knouf EC, Metzger MJ, Mitchell PS et al. Multiple integrated copies and high-level production of the human retrovirus XMRV (xenotropic murine leukemia virus-related virus) from 22Rv-1 prostate carcinoma cells. J Virol 2009; 83: 3753–3756.
32 Akbul B, Pfister D, Knuchel R, Heidenreich A, Wieland U, Pfister H. No evidence for a role of xenotropic murine leukemia virus-related virus and BK virus in prostate cancer of German patients. Med Microbiol Immunol 2012; 201: 245–248.
33 Akgul B, Blomme P et al. Lack of detection of XMRV in seminal plasma from HIV-1 infected men in The Netherlands. PLoS ONE 2010; 5: e12040.
34 Hohn O, Krause H, Barbarotto P et al. Lack of evidence for xenotropic murine leukemia virus-related virus (OMRV) in German prostate cancer patients. Retrovirology 2009; 6: 92.
35 Mendoza R, Silverman RH, Klein EA, Miller AD. No biological evidence of XMRV in blood of a pancreatic fluid from prostate cancer patients. PLoS ONE 2012; 7: e36073.
36 Sakuma T, Hue S, Squillace KA et al. No evidence of XMRV in prostate cancer cohorts in the Midwestern United States. Retrovirology 2011; 8: 23.
et al. Absence of xenotropic murine leukemia virus-related virus in UK patients with chronic fatigue syndrome. Retrovirology 2010; 7: 10.

Hong P, Li J, Li Y. Failure to detect xenotropic murine leukemia virus-related virus in Chinese patients with chronic fatigue syndrome. Virol J 2010; 7: 224.

Oakes B, Gru B, Levine S, Hackett J J, Huber BT. Failure to detect XMRV-specific antibodies in the plasma of CFS patients using highly sensitive chemiluminescence immunosassays. Adv Virol 2011; 2011: 854540.

Satterfield BC, Garcia RA, Jia H, Tang S, Zheng H, Switzer WM. Serologic and PCR testing of persons with chronic fatigue syndrome in the United States shows no association with xenotropic or polytropic murine leukemia virus-related viruses. Retrovirology 2011; 8: 12.

Simmons G, Giynna SN, Komaroff AL et al. Failure to confirm XMRVMLVs in the blood of patients with chronic fatigue syndrome: a multi-laboratory study. Science 2011; 333: 814-817.

Steifen I, Tyrell DL, Stein E et al. No evidence for XMRV nucleic acids, infectious virus or anti-XMRV antibodies in Canadian patients with chronic fatigue syndrome. PLoS ONE 2011; 6: e28780.

Stewart WM, Jia H, Inen O et al. Absence of evidence of xenotropic murine leukemia virus-related virus infection in persons with chronic fatigue syndrome and healthy controls in the United States. Retrovirology 2010; 7: 57.

Blomberg J, Blomberg F, Sisteen A et al. No evidence for xenotropic murine leukemia-related virus infection in one using internally controlled multipletopse suspension array serology. Clin Vaccine Immunol 2012; 19: 1399-1410.

Mi Z, Lu Y, Zhang S et al. Absence of xenotropic murine leukemia virus-related virus in blood donors in China. Transfusion 2012; 52: 326-331.

Qiu J, Swetzer P, Tang N et al. Senoencephalitis of xenotropic murine leukemia-related virus infection in normal and retrovirus-infected blood donors. Transfusion 2012; 52: 307-316.

Tang S, Zhao J, Halayei Giri Setty MK et al. Absence of detectable XMRV and other MLV-related viruses in healthy blood donors in the United States. PLoS ONE 2011; 6: e19391.

Barnes E, Flanagan P, Brown A et al. Failure to detect xenotropic murine leukemia virus-related virus-in blood of individuals at high risk of blood-borne viral infections. J Infect Dis 2010; 202: 1482-1485.

Delviks-Frankenberry KA, Chapin C, Bagari R, Wyvill K, Yarchan R, Pathak VK et al. Lack of xenotropic murine leukemia virus-related virus infection in HIV-1 lymphoma patients. Adv Virol 2011; 2011: 797820.

Gingras C, Danielon BP, Vigil K, Yee E, Arduin RC, Kimata JT. Absence of XMRV in peripheral blood mononuclear cells of ARV-treatment naive HIV-1 infected and HIV-1/ HCV coinfected individuals and blood donors. PLoS ONE 2012; 7: e31398.

Gray ER, Garson JA, Breuer J et al. No evidence of XMRV or related retroviruses in a London HIV-1 positive patient cohort. PLoS ONE 2011; 6: e18096.

He X, Walker TD, Marangia IO, Oliver AW, Hampson L, Hampson IN. No biological evidence of XMRV infection in cerebral swarms from HIV/HBV positive and negative Kenyan women. PLoS ONE 2012; 7: e47208.

Luzckowiaj J, Martinez-Prats L, Sierra O et al. Lack of the detection of XMRV or polytropic MLV-related sequences in blood cells from HIV-1-infected patients in Spain. J Acquir Immune Defic Syndr 2012; 62: 101-104.

Paprotka T, Venkatchari NJ, Chapin C et al. Inhibition of xenotropic murine leukemia virus-related virus by APOBEC3 proteins and antiviral drugs. J Virol 2010; 84: 5719-5729.

Boizard HP, Zhang F, Bieniasz PD, Cullen BR. Human APOBEC3 proteins can inhibit xenotropic murine leukemia virus-related virus infectivity. Virology 2011; 410: 234-239.

Stierle K, Fischer N. Apobec 3G efficiently reduces infectivity of the human exogenous gammaretrovirus XMRV. PLoS ONE 2010; 5: e11738.

Mardones LM, In vivo analysis of human T-cell leukemia virus type 1 transcripption accuracy. J Virol 2000; 74: 9525-9531.

Van Dooren S, Pybus OG, Salemi M et al. The low evolutionary rate of human T-cell lymphotropic virus type-1 confirmed by analysis of vertical transmission chains. Mol Biol Evol 2011; 28: 508-511.

Paprotka T, Delviks-Frankenberry KA, Cingoz O et al. Reemergent origin of the retrovirus XMRV. Science 2011; 333: 97-101.

Delviks-Frankenberry K, Paprotka T, Cingoz O et al. Generation of multiple replication-competent retroviruses through recombination between PreXMRV-1 and PreXMRV-2. J Virol 2013; 87: 11525-11537.

Lee D, da Guada J, Gaught C et al. In-depth investigation of archival and prospectively collected samples reveals no evidence for XMRV infection in prostate cancer. PLoS ONE 2012; 7: e44954.

Silverman RH, da Guada J, Lombardi VC et al. Partial retraction. Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome. Science 2011; 334: 176.

Knox C, Carrigan D, Simmons G et al. No evidence of murine-like gammaretroviruses in CFS patients previously identified as XMRV-infected. Science 2011; 333: 94-97.

Shin CH, Bateman L, Schlabig R et al. Absence of XMRV retrovirus and other murine leukemia-virus-related viruses in patients with chronic fatigue syndrome. J Virol 2011; 85: 7195-7202.

Silverman RH, da Guada J, Lombardi VC et al. Partial retraction. Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome. Science 2011; 334: 176.

Orlandon M, da Guada J, Sharma P et al. Infection, viral dissemination, and antibody responses of rhesus macaques exposed to the human gammaretrovirus XMRV. J Virol 2011; 85: 4547-4557.